[EN] METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE TRIAZOLOPYRIDINES SUBSTITUÉES
申请人:BAYER PHARMA AG
公开号:WO2014009219A1
公开(公告)日:2014-01-16
The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.
METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES
申请人:BAYER PHARMA AKTIENGESELLSCHAFT
公开号:US20150148542A1
公开(公告)日:2015-05-28
The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.
The present invention relates to triazolopyridine compounds of general formula (I): in which R
1
, R
2
, R
3
, R
4
, and R
5
are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
[EN] COMBINATIONS FOR THE TREATMENT OF CANCER<br/>[FR] COMBINAISONS POUR LE TRAITEMENT DU CANCER
申请人:BAYER PHARMA AG
公开号:WO2014020043A1
公开(公告)日:2014-02-06
The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti-apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.